Literature DB >> 24901414

Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons.

Sung Woo Park1, Jung Goo Lee1, Mi Kyoung Seo1, Chan Hong Lee1, Hye Yeon Cho1, Bong Ju Lee2, Wongi Seol3, Young Hoon Kim1.   

Abstract

Recent studies suggest that ketamine produces antidepressant actions via stimulation of mammalian target of rapamycin (mTOR), leading to increased levels of synaptic proteins in the prefrontal cortex. Thus, mTOR activation may be related to antidepressant action. However, the mTOR signalling underlying antidepressant drug action has not been well investigated. The aim of the present study was to determine whether alterations in mTOR signalling were observed following treatment with antidepressant drugs, using ketamine as a positive control. Using Western blotting, we measured changes in the mTOR-mediated proteins and synaptic proteins in rat hippocampal cultures. Dendritic outgrowth was determined by neurite assay. Our findings demonstrated that escitalopram, paroxetine and tranylcypromine significantly increased levels of phospho-mTOR and its down-stream regulators (phospho-4E-BP-1 and phospho-p70S6K); fluoxetine, sertraline and imipramine had no effect. All drugs tested increased up-stream regulators (phospho-Akt and phospho-ERK) levels. Increased phospho-mTOR induced by escitalopram, paroxetine or tranylcypromine was significantly blocked in the presence of specific PI3K, MEK or mTOR inhibitors, respectively. All drugs tested also increased hippocampal dendritic outgrowth and synaptic proteins levels. The mTOR inhibitor, rapamycin, significantly blocked these effects on escitalopram, paroxetine and tranylcypromine whereas fluoxetine, sertraline and imipramine effects were not affected. The effects of escitalopram, paroxetine and tranylcypromine paralleled those of ketamine. This study presents novel in vitro evidence indicating that some antidepressant drugs promote dendritic outgrowth and increase synaptic protein levels through mTOR signalling; however, other antidepressant drugs seem to act via a different pathway. mTOR signalling may be a promising target for the development of new antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24901414     DOI: 10.1017/S1461145714000534

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  36 in total

1.  Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.

Authors:  Ashley E Lepack; Eunyoung Bang; Boyoung Lee; Jason M Dwyer; Ronald S Duman
Journal:  Neuropharmacology       Date:  2016-09-12       Impact factor: 5.250

2.  Cacna1c in the Prefrontal Cortex Regulates Depression-Related Behaviors via REDD1.

Authors:  Zeeba D Kabir; Anni S Lee; Caitlin E Burgdorf; Delaney K Fischer; Aditi M Rajadhyaksha; Ethan Mok; Bryant Rizzo; Richard C Rice; Kamalpreet Singh; Kristie T Ota; Danielle M Gerhard; Kathryn C Schierberl; Michael J Glass; Ronald S Duman; Anjali M Rajadhyaksha
Journal:  Neuropsychopharmacology       Date:  2016-12-06       Impact factor: 7.853

3.  Behavioral and biochemical sensitivity to low doses of ketamine: Influence of estrous cycle in C57BL/6 mice.

Authors:  Amanda M Dossat; Katherine N Wright; Caroline E Strong; Mohamed Kabbaj
Journal:  Neuropharmacology       Date:  2017-11-21       Impact factor: 5.250

Review 4.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

5.  Involvement of PI3K/Akt Signaling Pathway and Its Downstream Intracellular Targets in the Antidepressant-Like Effect of Creatine.

Authors:  Mauricio P Cunha; Josiane Budni; Fabiana K Ludka; Francis L Pazini; Julia Macedo Rosa; Ágatha Oliveira; Mark W Lopes; Carla I Tasca; Rodrigo B Leal; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2015-05-06       Impact factor: 5.590

6.  Ketamine Exhibits Different Neuroanatomical Profile After Mammalian Target of Rapamycin Inhibition in the Prefrontal Cortex: the Role of Inflammation and Oxidative Stress.

Authors:  Helena M Abelaira; Gislaine Z Réus; Zuleide M Ignácio; Maria Augusta B Dos Santos; Airam B de Moura; Danyela Matos; Júlia P Demo; Júlia B I da Silva; Lucineia G Danielski; Fabricia Petronilho; André F Carvalho; João Quevedo
Journal:  Mol Neurobiol       Date:  2016-09-02       Impact factor: 5.590

7.  Gallic acid activates hippocampal BDNF-Akt-mTOR signaling in chronic mild stress.

Authors:  Ji-Xiao Zhu; Jia-Ling Shan; Wei-Qiong Hu; Jin-Xiang Zeng; Ji-Cheng Shu
Journal:  Metab Brain Dis       Date:  2018-10-03       Impact factor: 3.584

Review 8.  New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.

Authors:  Zuleide M Ignácio; Gislaine Z Réus; Camila O Arent; Helena M Abelaira; Meagan R Pitcher; João Quevedo
Journal:  Br J Clin Pharmacol       Date:  2016-01-08       Impact factor: 4.335

9.  Molecular network of neuronal autophagy in the pathophysiology and treatment of depression.

Authors:  Jack Jia; Weidong Le
Journal:  Neurosci Bull       Date:  2015-08-08       Impact factor: 5.203

10.  Tianeptine induces mTORC1 activation in rat hippocampal neurons under toxic conditions.

Authors:  Mi Kyoung Seo; Roger S McIntyre; Hye Yeon Cho; Chan Hong Lee; Sung Woo Park; Rodrigo B Mansur; Gyung-Mee Kim; Jun Hyung Baek; Young Sup Woo; Jung Goo Lee; Young Hoon Kim
Journal:  Psychopharmacology (Berl)       Date:  2016-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.